An expanded access record providing SAGE-547 in Super-Refractory Status Epilepticus, sponsored by Supernus Pharmaceuticals, Inc.. No longer available. Open to participants aged 6 Months and older. Per ClinicalTrials.gov, last updated 2025-09-15.
Sponsored by Supernus Pharmaceuticals, Inc. · Expanded access
This is an open-label, expanded access protocol, designed to offer treatment with SAGE-547 to subjects in SRSE, and to evaluate the efficacy and safety of SAGE-547 administered as a continuous intravenous infusion to these subjects
Supernus Pharmaceuticals, Inc. is the lead sponsor of 61 studies on the registry; 6 are open to participants now.
Of its 31 completed or terminated interventional studies of FDA-regulated products, 25 (81%) have results posted.
Counted across the registry records on this site, refreshed daily.
Subjects who have:
Exclusion Criteria:
Subjects who have any of the following:
No study locations are listed for this record.
Expanded access is arranged between your doctor and the company. Ask your care team to contact the provider listed on this record.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Supernus Pharmaceuticals, Inc.